Autoimmune hemolytic anemia differential diagnosis

Revision as of 11:26, 20 September 2018 by Mmir (talk | contribs)
Jump to navigation Jump to search

Autoimmune hemolytic anemia Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Autoimmune hemolytic anemia from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

Diagnostic Study of Choice

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

X-ray

Echocardiography and Ultrasound

CT

MRI

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Autoimmune hemolytic anemia differential diagnosis On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Autoimmune hemolytic anemia differential diagnosis

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Autoimmune hemolytic anemia differential diagnosis

CDC on Autoimmune hemolytic anemia differential diagnosis

Autoimmune hemolytic anemia differential diagnosis in the news

Blogs on Autoimmune hemolytic anemia differential diagnosis

Directions to Hospitals Treating Autoimmune hemolytic anemia

Risk calculators and risk factors for Autoimmune hemolytic anemia differential diagnosis

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Assosciate Editor(s)-In-Chief: Prashanth Saddala M.B.B.S; Shyam Patel [2], Irfan Dotani [3]

Overview

A variety of conditions comprise the differential diagnosis of autoimmune hemolytic anemia. These include microangiopathic hemolytic anemia, paroxysmal cold hemoglobinuria, paroxysmal nocturnal hemoglobinuria, hereditary spherocytosis, pernicious anemia, and chronic lymphocytic leukemia. The diagnosis of autoimmune hemolytic anemia can sometimes be made by first ruling out these other causes. It is important to distinguish amongst these conditions since the prognosis and treatment of each condition is different.

Differentiating Autoimmune hemolytic anemia from other Diseases

Differential diagnosis of "Bleeding disorders":

Category Sub-category Diseases History Clinical manifestation Laboratory testing Comments
Petechia|Petechiae Ecchymoses Menorrhagia Hematoma Hemarthrosis Platelet count Bleeding time (BT) Prothrombin time (PT) Activated partial thromboplastin time (aPTT) Thrombin time (TT)
Platelet disorders Thrombocytopenia Infection-Induced thrombocytopenia[1][2][3]
  • History of prior infection
+ + + + + N N N -
Medications-Induced thrombocytopenia [4][5] + + + + + N N N Most important par of treatment is discontinuing of the medication.
Heparin-Induced thrombocytopenia[6] + + + + + N N For more information click here: Heparin-induced thrombocytopenia.
Immune Thrombocytopenic Purpura (ITP)[7] + + + + + N N N -
Inherited Thrombocytopenia[8][9]
  • Family history
+ + + + + N N N -
Thrombotic Thrombocytopenic Purpura (TTP)[10][11] History of: + + + + + N N N -
Hemolytic Uremic Syndrome[12][13] History of:
  • Infections
+ + + + + N N N -
Thromobcytosis Iron deficiency anemia

Inflammatory diseases

Splenectomy

Essential thrombocytosis

+/- +/- Ν/↑ ɴ ɴ N -
Qualitative Disorders of Platelet Function Inherited Disorders of Platelet Function Glanzmann’s thrombasthenia
  • Positive family history
+ + + - Rare N/↓ ɴ ɴ N
  • AR inheritance
  • Absence of the platelet Gp IIb/IIIa receptor/
  • Diminished for GP 2B-3A on flow cytometry
Bernard-Soulier syndrome[14][15]
  • Positive family history
+ + + - - N/↓ N N N
  • AR inheritance
  • Absence of the platelet Gp Ib-IX-V receptor
  • On PBS: giant platelets
  • Ristocetin - no aggregation
Platelet storage pool disorder (SPD):
  • Positive family history
  • Hairy-cell leukemia
  • Cardiovascular bypass
+ + + - - N/↓ N N N
  • AD inheritance
  • Abnormalities of platelet granule formation
Acquired Disorders of Platelet Function + + + +/- +/- N/↓ N N N -
Von Willebrand Disease [16][16][17][18][19] + + + +/- +/- Ν N See the table below for the details about types.
Vessel wall disorders Metabolic and Inflammatory Disorders
  • History of the underlying disease.
+ + +/- - - N ↑/N N N N -
Inherited Disorders of the Vessel Wall
  • Positive family history
+ + +/- - - N ↑/N N N N -
Coagulation factor disorders Fibrinogen deficiency Different types of the fibrinogen disorders: _ + + +/- + N
  • Impaired fibrin cross linking or clot dissolution.
  • The severity of bleeding in patients with fibrinogen disorders can be mild or severe, with higher bleeding risk in those with afibrinogenemia or lower levels of functional fibrinogen. The age of onset is also variable, with earlier onset in those with more severe deficiency.
Prothrombin deficiency + + + + + N N -
Factor V deficiency _ + + + + N N The severity of bleeding is only partly related to the degree of factor V deficiency. Some patients with undetectable plasma levels of factor V experience only relatively mild bleeding.
Factor VII deficiency + + + N N N Thrombosis occurs in inherited factor VII deficiency most cases are associated with the administration of factor VII replacement therapy
Factor X deficiency
  • Prolonged bleeding following circumcision
+ + + + + N N N -
Factor XII deficiency
  • Majority,asymptomatic
  • Recurrent miscarriages
  • Painful leg ulcers
_ _ _ _ _ N N N N
High molecular weight kininogen (HMWK) deficiency
  • Possibility of positive family history of bleeding
_ _ _ _ _ N N N N
Prekallikrein deficiency
  • Possibility of positive family history of bleeding
_ _ _ _ _ N N N N
Factor XIII deficiency Types:
  • Sub unit A mutation disease (more common)
  • Sub unit B mutation disease
  • Possibility of positive family history of bleeding
-/+ -/+ -/+ -/+ -/+ N N/ N/↑ N N
  • Impaired fibrin cross linking or clot dissolution
  • The severity of factor XIII deficiency bleeds can be different in different patients
Hemophilia[20][21][22][23][24][25] Type A deficiency _ _ + + + N N N N -
Type B deficiency _ _ + + + N N N N -
Type C deficiency
  • Family history
  • Bleeding after surgery or injury
_ _ + Rare Rare N N N N -
Rare diseases Disseminated Intravascular Coagulation + + _ + + N -
Vitamin K Deficiency + + + + + N Normal or mildly prolonged N -
Different types of Von-Willebrand diseases can be differentiated from each other based on the following table:[26]
Type of VWD Type of factor deficiency Prevalence Inheritance pattern Clinical manifestations VWF activity RIPA Factor VIII
Type 1 Quantitative/ partial 60-70% AD
  • Bleeding severity mild to severe
Type 2 2A[27] Qualitative 10% AD/AR
  • Moderate to severe bleeding
N or ↓
2B Qualitative 5% AD N or↓
2M Qualitative <1% AD/AR
  • Moderate to severe bleeding
N or ↓
2N Qualitative <1% AR
  • Clinically similar to hemophilia A with joint, soft tissue, urinary bleeding
N N
Type 3 Complete deficiency 1-2% AR Absent

Low, 1-10%

For more information on Von Willebrand disease click here

Characteristic Causes Pathophysiology Laboratory abnormalities Physical examination Therapy Other associations
Autoimmune hemolytic anemia
  • Polyclonal antibody production that binds to and targets red blood cells for destruction intravascurly or extravascularly[28]
  • Removal of offending agent
  • Corticosteroids
  • Cyclophosphamide
  • Cyclosporine A
  • Azathioprine
  • Rituximab
  • Splenectomy
  • Hemolysis can occur at warm or cold temperatures
Microangiopathic hemolytic anemia
  • Formation of small vessel microthombi
  • Bleeding
  • Thrombosis
  • Pyrexia
  • Altered mental status
  • Neurologic deficits
  • Impaired urine output
  • Can be life-threatening pending the underlying cause
  • TTP required immediate treatment
Paroxysmal cold hemoglobinuria
  • Biphasic hemolysin (IgG) that binds red blood cells and low temperatures and triggers complement-mediated intravascular hemolysis at warm temperatures[29]
  • Associated with syphilis[29]
  • Maternal IgG can cross the placenta and affect the fetus[29]
Paroxysmal nocturnal hemoglobinuria
  • Genetic defect in anchoring proteins for complement factors on red blood cells
  • Hemolysis due to loss of complement inhibition on the red blood cell surface, which in turn is due to defect in CD55 (decay accelerating factor) and CD59 (membrane inhibitor of reactive lysis) or other glycophosphatidylinositol-anchored proteins on the red blood cell membrane
  • Absence of CD55 and CD59 by flow cytometry
  • Splenomegaly
  • Abdominal tenderness
  • Pallor
Hereditary spherocytosis[30]
  • Mutation in ankyrin[30]
  • Mutation in alpha- or beta-spectrin[30]
  • Mutation in band 3[30]
  • Mutation in protein 4.2[30]
  • Positive eosin-5-maleimide binding to red blood cells[30]
  • Positive osmotic fragility testing[30]
  • Spherocytes on peripheral blood smear
  • Can be autosomal dominant or recessive
Pernicious anemia[31]
  • Autoimmune gastritis[31]
  • Production of anti-intrinsic factor antibodies[31]
  • Production of anti-parietal cell antibodies[31]
  • Impaired vitamin B12 absorption due to absence of intrinsic factor
  • Low vitamin B12 level
  • Presence of anti-intrinsic factor antibodies
  • Presence of anti-parietal cell antibodies
  • Associated with diabetes, thyroid disease, vitiligo and other autoimmune conditions
Chronic lymphocytic leukemia[32]
  • Mutations in hematopoietic stem cells and B lymphocytes
  • Clonal proliferation of malignant B lymphocytes
  • Elevated absolute lymphocyte count
  • Anemia (Rai stage III) and thrombocytopenia (Rai stage IV)
  • Chemotherapy with rituximab
  • Ibrutinib
  • Venetoclax
  • Secondary autoimmune hemolytic anemia occurs in 10-25% of patients with CLL
  • Treatment with corticosteroids or anti-leukemic therapy will correct the underlying anemia

References

  1. Neunert C, Lim W, Crowther M, Cohen A, Solberg L, Crowther MA (April 2011). "The American Society of Hematology 2011 evidence-based practice guideline for immune thrombocytopenia". Blood. 117 (16): 4190–207. doi:10.1182/blood-2010-08-302984. PMID 21325604.
  2. Karimi O, Goorhuis A, Schinkel J, Codrington J, Vreden S, Vermaat JS, Stijnis C, Grobusch MP (March 2016). "Thrombocytopenia and subcutaneous bleedings in a patient with Zika virus infection". Lancet. 387 (10022): 939–940. doi:10.1016/S0140-6736(16)00502-X. PMID 26906627. Vancouver style error: initials (help)
  3. Zammarchi L, Stella G, Mantella A, Bartolozzi D, Tappe D, Günther S, Oestereich L, Cadar D, Muñoz-Fontela C, Bartoloni A, Schmidt-Chanasit J (February 2015). "Zika virus infections imported to Italy: clinical, immunological and virological findings, and public health implications". J. Clin. Virol. 63: 32–5. doi:10.1016/j.jcv.2014.12.005. PMID 25600600.
  4. Kam T, Alexander M (October 2014). "Drug-induced immune thrombocytopenia". J Pharm Pract. 27 (5): 430–9. doi:10.1177/0897190014546099. PMID 25134884.
  5. Seco-Melantuche R, Delgado-Sánchez O, Álvarez-Arroyo L (2013). "[Incidence of drug-induced thrombocytopenia in hospitalized patients]". Farm Hosp (in Spanish; Castilian). 37 (1): 27–34. doi:10.7399/FH.2013.37.1.42. PMID 23461497.
  6. Warkentin TE, Safyan EL, Linkins LA (January 2015). "Heparin-induced thrombocytopenia presenting as bilateral adrenal hemorrhages". N. Engl. J. Med. 372 (5): 492–4. doi:10.1056/NEJMc1414161. PMID 25629757.
  7. Wright JF, Blanchette VS, Wang H, Arya N, Petric M, Semple JW, Chia WK, Freedman J (October 1996). "Characterization of platelet-reactive antibodies in children with varicella-associated acute immune thrombocytopenic purpura (ITP)". Br. J. Haematol. 95 (1): 145–52. PMID 8857953.
  8. Johnson B, Fletcher SJ, Morgan NV (September 2016). "Inherited thrombocytopenia: novel insights into megakaryocyte maturation, proplatelet formation and platelet lifespan". Platelets. 27 (6): 519–25. doi:10.3109/09537104.2016.1148806. PMC 5000870. PMID 27025194.
  9. Wang Q, Cao L, Sheng G, Shen H, Ling J, Xie J, Ma Z, Yin J, Wang Z, Yu Z, Chen S, Zhao Y, Ruan C, Xia L, Jiang M (August 2018). "Application of High-Throughput Sequencing in the Diagnosis of Inherited Thrombocytopenia". Clin. Appl. Thromb. Hemost.: 1076029618790696. doi:10.1177/1076029618790696. PMID 30103613.
  10. Knöbl P (2018). "Thrombotic thrombocytopenic purpura". Memo. 11 (3): 220–226. doi:10.1007/s12254-018-0429-6. PMID 30220931.
  11. Mannucci PM, Cugno M (November 2015). "The complex differential diagnosis between thrombotic thrombocytopenic purpura and the atypical hemolytic uremic syndrome: Laboratory weapons and their impact on treatment choice and monitoring". Thromb. Res. 136 (5): 851–4. doi:10.1016/j.thromres.2015.09.007. PMID 26386489.
  12. Webster K, Schnitzler E (2014). "Hemolytic uremic syndrome". Handb Clin Neurol. 120: 1113–23. doi:10.1016/B978-0-7020-4087-0.00075-9. PMID 24365375.
  13. Picard C, Burtey S, Bornet C, Curti C, Montana M, Vanelle P (June 2015). "Pathophysiology and treatment of typical and atypical hemolytic uremic syndrome". Pathol. Biol. 63 (3): 136–43. doi:10.1016/j.patbio.2015.03.001. PMID 25845294.
  14. Dupuis A, Gachet C (September 2018). "Inherited platelet disorders : Management of the bleeding risk". Transfus Clin Biol. 25 (3): 228–235. doi:10.1016/j.tracli.2018.07.003. PMID 30077511.
  15. Andres O, Henning K, Strauß G, Pflug A, Manukjan G, Schulze H (June 2018). "Diagnosis of platelet function disorders: A standardized, rational, and modular flow cytometric approach". Platelets. 29 (4): 347–356. doi:10.1080/09537104.2017.1386297. PMID 29227167.
  16. 16.0 16.1 Elbatarny M, Mollah S, Grabell J, Bae S, Deforest M, Tuttle A, Hopman W, Clark DS, Mauer AC, Bowman M, Riddel J, Christopherson PA, Montgomery RR, Rand ML, Coller B, James PD (November 2014). "Normal range of bleeding scores for the ISTH-BAT: adult and pediatric data from the merging project". Haemophilia. 20 (6): 831–5. doi:10.1111/hae.12503. PMC 4251588. PMID 25196510.
  17. Goodeve A, Eikenboom J, Castaman G, Rodeghiero F, Federici AB, Batlle J, Meyer D, Mazurier C, Goudemand J, Schneppenheim R, Budde U, Ingerslev J, Habart D, Vorlova Z, Holmberg L, Lethagen S, Pasi J, Hill F, Hashemi Soteh M, Baronciani L, Hallden C, Guilliatt A, Lester W, Peake I (January 2007). "Phenotype and genotype of a cohort of families historically diagnosed with type 1 von Willebrand disease in the European study, Molecular and Clinical Markers for the Diagnosis and Management of Type 1 von Willebrand Disease (MCMDM-1VWD)". Blood. 109 (1): 112–21. doi:10.1182/blood-2006-05-020784. PMID 16985174.
  18. Mammen EF, Comp PC, Gosselin R, Greenberg C, Hoots WK, Kessler CM, Larkin EC, Liles D, Nugent DJ (1998). "PFA-100 system: a new method for assessment of platelet dysfunction". Semin. Thromb. Hemost. 24 (2): 195–202. doi:10.1055/s-2007-995840. PMID 9579642.
  19. Bodó I, Eikenboom J, Montgomery R, Patzke J, Schneppenheim R, Di Paola J (July 2015). "Platelet-dependent von Willebrand factor activity. Nomenclature and methodology: communication from the SSC of the ISTH". J. Thromb. Haemost. 13 (7): 1345–50. doi:10.1111/jth.12964. PMC 5576173. PMID 25858564.
  20. Aviña-Zubieta JA, Galindo-Rodriguez G, Lavalle C (January 1998). "Rheumatic manifestations of hematologic disorders". Curr Opin Rheumatol. 10 (1): 86–90. PMID 9448995.
  21. Plug I, Mauser-Bunschoten EP, Bröcker-Vriends AH, van Amstel HK, van der Bom JG, van Diemen-Homan JE, Willemse J, Rosendaal FR (July 2006). "Bleeding in carriers of hemophilia". Blood. 108 (1): 52–6. doi:10.1182/blood-2005-09-3879. PMID 16551972.
  22. Blanchette VS, Key NS, Ljung LR, Manco-Johnson MJ, van den Berg HM, Srivastava A (November 2014). "Definitions in hemophilia: communication from the SSC of the ISTH". J. Thromb. Haemost. 12 (11): 1935–9. doi:10.1111/jth.12672. PMID 25059285.
  23. White GC, Rosendaal F, Aledort LM, Lusher JM, Rothschild C, Ingerslev J (March 2001). "Definitions in hemophilia. Recommendation of the scientific subcommittee on factor VIII and factor IX of the scientific and standardization committee of the International Society on Thrombosis and Haemostasis". Thromb. Haemost. 85 (3): 560. PMID 11307831.
  24. Favaloro EJ, Meijer P, Jennings I, Sioufi J, Bonar RA, Kitchen DP, Kershaw G, Lippi G (October 2013). "Problems and solutions in laboratory testing for hemophilia". Semin. Thromb. Hemost. 39 (7): 816–33. doi:10.1055/s-0033-1356573. PMID 24026910.
  25. Blanchette VS, Key NS, Ljung LR, Manco-Johnson MJ, van den Berg HM, Srivastava A (November 2014). "Definitions in hemophilia: communication from the SSC of the ISTH". J. Thromb. Haemost. 12 (11): 1935–9. doi:10.1111/jth.12672. PMID 25059285.
  26. Bodó I, Eikenboom J, Montgomery R, Patzke J, Schneppenheim R, Di Paola J (July 2015). "Platelet-dependent von Willebrand factor activity. Nomenclature and methodology: communication from the SSC of the ISTH". J. Thromb. Haemost. 13 (7): 1345–50. doi:10.1111/jth.12964. PMC 5576173. PMID 25858564.
  27. Lyons SE, Bruck ME, Bowie EJ, Ginsburg D (March 1992). "Impaired intracellular transport produced by a subset of type IIA von Willebrand disease mutations". J. Biol. Chem. 267 (7): 4424–30. PMID 1537829.
  28. 28.0 28.1 28.2 Berentsen S, Sundic T (2015). "Red blood cell destruction in autoimmune hemolytic anemia: role of complement and potential new targets for therapy". Biomed Res Int. 2015: 363278. doi:10.1155/2015/363278. PMC 4326213. PMID 25705656.
  29. 29.0 29.1 29.2 29.3 Akpoguma AO, Carlisle TL, Lentz SR (2015). "Case report: paroxysmal cold hemoglobinuria presenting during pregnancy". BMC Hematol. 15: 3. doi:10.1186/s12878-015-0023-7. PMC 4334594. PMID 25699184.
  30. 30.0 30.1 30.2 30.3 30.4 30.5 30.6 30.7 Gallagher PG (2013). "Abnormalities of the erythrocyte membrane". Pediatr Clin North Am. 60 (6): 1349–62. doi:10.1016/j.pcl.2013.09.001. PMC 4155395. PMID 24237975.
  31. 31.0 31.1 31.2 31.3 31.4 Chan CQ, Low LL, Lee KH (2016). "Oral Vitamin B12 Replacement for the Treatment of Pernicious Anemia". Front Med (Lausanne). 3: 38. doi:10.3389/fmed.2016.00038. PMC 4993789. PMID 27602354.
  32. Kipps TJ, Stevenson FK, Wu CJ, Croce CM, Packham G, Wierda WG; et al. (2017). "Chronic lymphocytic leukaemia". Nat Rev Dis Primers. 3: 16096. doi:10.1038/nrdp.2016.96. PMC 5336551. PMID 28102226.


Template:WikiDoc Sources